US has no immediate plans to share Covid vaccines with India amid record-breaking surge
India is one of the world’s largest vaccine makers, but has struggled to maintain enough supply for its population amid a massive Covid surge
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
The US has no immediate plans to aid the Indian government and share its stockpile of vaccines, even as the country experiences a record-breaking surge and Indian hospitals are struggling to find enough beds or bottled oxygen for patients.
India announced 332,730 new coronavirus cases on Friday, the second day in a row it has set a new world record.
US officials say they aiding the Indian government’s public health agency with technical support and other assistance, but don’t have immediate plans to share extra vaccine supplies. That includes not sending doses from the US stockpile of the AstraZeneca vaccine, which is not yet approved for use in America.
America is “committed to sharing vaccine supply,” White House coronavirus coordinator Jeff Zients said at a recent briefing, though only once the country feels more secure in its own supply.
“As our confidence around our supply increases, we will explore those options,” he said.
The US has pledged up to $4 billion to Covax, the international effort to provide vaccines to low-income countries, and is in discussions to share supplies like ventilators with India. It is also part of an effort to boost vaccine manufacturing in the US, India, Japan and Australia through 2022.
“It is a dire situation that we’re trying to help in any way we can,” White House Covid adviser Dr Anthony Fauci said at Friday’s coronavirus briefing.
India is one of the world’s largest manufacturers of vaccines, but has struggled with an internal covid crisis. The country has had roughly 16 million Covid cases overall, and medical facilities have struggled with low bed space and access to bottled oxygen, while authorities have allowed massive election rallies and religious festivals to take place in recent days, including the Hindu festival of Kumbh Mela, which drew millions of people.
Experts say the country is suffering because of mixed messaging and implementation of public health initiatives around Covid, and political leaders who celebrated victory over Covid prematurely, allowing people to let their guard down.
India’s inability to provide widespread vaccination to large parts of its population also highlights the bind of many middle- and low-income countries, who could wait until as long as 2023 before achieving mass vaccination, as rich nations hoover up global vaccine supply.
In March, Indian authorities slowed vaccine exports to other nations to shore up the domestic supply.
58 low- and middle-income countries, as well as US legislators like senator Bernie Sanders, have urged pharma giants and the World Trade Organization to facilitate open-access use of patented vaccine fomulas to speed up distribution.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments